Navigation Links
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Date:9/10/2007

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) regarding its proposed 505(b)(2) New Drug Application (NDA) regulatory path for ANX-514 (docetaxel emulsion). The FDA has indicated that data from a single study of approximately 28 patients that demonstrates the bioequivalence of ANX-514 and docetaxel is sufficient to support filing an NDA. Docetaxel is an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers, and is marketed under the brand name Taxotere(R). Annual sales of Taxotere in 2006 were approximately $2.2 billion.

"This guidance from the FDA is significant as conducting a single marketing-enabling trial provides us a clear and direct clinical path and substantially shortens the timelines for clinical development and submitting an NDA for ANX-514," said Evan M. Levine, chief executive officer of ADVENTRX. "Pending appropriate clearances, we look forward to starting the proposed bioequivalence trial later this year."

The Company currently plans to submit an investigational new drug (IND) application in the fourth quarter of 2007. The proposed clinical trial will compare the blood levels of docetaxel following a single dose of ANX-514 or Taxotere in patients with advanced cancers. In addition, the Company plans to analyze the safety of ANX-514.

ANX-514 Preclinical Results

Preclinical results have demonstrated equivalent pharmacoki
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... 22, 2015 Dr. Greg Leyer of UAS ... Scripps Natural Supplements Pre-Conference seminar on probiotics in San Diego, ... annual continuing education conference for health care professionals. This year’s ... topic of probiotics in health. Dr. Leyer spoke about the ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Novavax, Inc. (Nasdaq: NVAX ) today announced that ... press release to be issued after 8:00 a.m. Eastern Time on ... call to discuss its financial results at 10:00 a.m. Eastern Time ... Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other ...
... July 31 Insmed Inc. (Nasdaq: INSM ), ... conference call on Thursday, August 13(th), at 8:30 AM ET, ... Insmed intends to issue its quarterly financial results press ... , To participate in the live conference call, ...
... LA JOLLA, Calif., July 30 TorreyPines ... has cancelled its Special Meeting of Stockholders, scheduled for today at ... stockholder to vote upon a proposal to approve the liquidation and ... and Plan of Merger by and between TPTX and Raptor Pharmaceuticals ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 3TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 4
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... frequently causes gastric ulcers and is also one of the ... infection is also associated with another gastric cancer risk factor, ... Clinical Investigation , researchers led by Richard Peek at Vanderbilt ... -induced gastric cancer. Peek and colleagues found that low iron ...
... in German . The climate after ... was cool, later very warm and then cool again. Thanks ... as paleontologists from the University of Zurich have reconstructed. The ... atmosphere, initially gave rise to new, short-lived species. In the ...
... This press release is available in German . ... produce energy from waste in biogas plants. Researchers from Bielefeld ... to find out which microbes do the best job. They ... in selected biogas plants up and down Germany. From the ...
Cached Biology News:Ironing out the link between H. pylori infection and gastric cancer 2Ups and downs of biodiversity after mass extinction 2A giant puzzle with billions of pieces 2A giant puzzle with billions of pieces 3
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... staining is a technique used to reveal ... PicTure™-Double Staining Kit is a Zymed polymer ... antigens simultaneously in the same human cell ... antigens can be identified using two different ...
... The FLUOstar OPTIMA is a ... built for life science labs in ... four different measurement principles: Fluorescence ... applications Time-Resolved Fluorescence including ...
... Digital Clamp One can operate as a Voltage ... Conductance (Dynamic) Clamp in electrophysiology research applications. Performance ... conventional analog equipment. • ... recent advances in the capabilities of Digital Signal ...
Biology Products: